Kiniksa Pharmaceuticals International (KNSA) Change in Receivables (2021 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Change in Receivables came in at $266000.0 in Q2 2026, up 103.26% YoY from $130865.7 in Q2 2025, and down 96.51% on a QoQ basis from $7.6 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Change in Receivables (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 6 years of Change in Receivables data on file, last reported at $266000.0 in Q2 2026.
- Quarterly Change in Receivables rose 103.26% year-over-year to $266000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$8.4 million (down 173.48% YoY) and the FY2025 annual result came in at -$26.1 million, down 227.73% from the prior year.
- Change in Receivables slipped to $266000.0 in Q2 2026, from $7.6 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $25.5 million in Q1 2022 to a low of -$36.1 million in Q4 2025.
- A 5-year average of $1.1 million and a median of $2.4 million in 2022 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 1114.19% in 2023, down 744.85% in 2023.
- Tracing KNSA's Change in Receivables over 5 years: stood at $1.5 million in 2022, then jumped by 1114.19% to $18.2 million in 2023, then declined by 7.62% to $16.8 million in 2024, then plunged by 314.71% to -$36.1 million in 2025, then jumped by 100.74% to $266000.0 in 2026.
- The last three Change in Receivables figures came in at $266000.0 (Q2 2026), $7.6 million (Q1 2026), and -$36.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.08 Bn | 5.56 Bn | 220.03 Mn | 266,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 266,000.00 |
| Jun 30, 2026 | 266,000.00 |
| Mar 31, 2026 | 7.63 Mn |
| Mar 31, 2026 | 7.63 Mn |
| Dec 31, 2025 | -36.15 Mn |
| Dec 31, 2025 | -36.15 Mn |
| Sep 30, 2025 | 19.83 Mn |
| Sep 30, 2025 | 19.83 Mn |
| Jun 30, 2025 | -8.16 Mn |
| Jun 30, 2025 | -8.16 Mn |
| Mar 31, 2025 | -1.66 Mn |
| Mar 31, 2025 | -1.66 Mn |
| Dec 31, 2024 | 16.84 Mn |
| Dec 31, 2024 | 16.84 Mn |
| Sep 30, 2024 | 4.44 Mn |
| Sep 30, 2024 | 4.44 Mn |
| Jun 30, 2024 | 4.46 Mn |
| Jun 30, 2024 | 4.46 Mn |
| Mar 31, 2024 | -5.27 Mn |
| Mar 31, 2024 | -5.27 Mn |